TABLE 1

Combination versus single-agent chemotherapy trials in second-line nonsmall cell lung cancer

First author, year [ref.]	Phase	Patients	Arms	PFS months	p-value	OS months	p-value	Response rate %	p-value
Pallis, 2010 [23]	III	132	Docetaxel + carboplatin	3.33	0.012	10.3	0.55	10.4	0.764
Pallis, 2010 [23]	III	132	Docetaxel	2.60		7.70		7.7
Takeda, 2009 [22]	III	130	Docetaxel + gemcitabine	2.8	0.028	10.3	0.36	7.0	0.71
Takeda, 2009 [22]	III	130	Docetaxel	2.1		10.1		6.8
Gebbia, 2009 [5]	III	84	Docetaxel	12.4 weeks	0.44	40 weeks	0.18	6.4	NR
			Docetaxel + vinorelbine or gemcitabine	13.1 weeks	0.60	32.6 weeks	0.90	16.7
			Docetaxel + capecitabine	11.9 weeks		39.7 weeks		5.3
Ardizzoni, 2012 [25]	II	479	Pemetrexed + carboplatin	3.9	0.70	8.7	0.316	15	0.062
Ardizzoni, 2012 [25]	II	479	Pemetrexed	3.0		8.2		9
Smit, 2009 [24]	II	240	Pemetrexed + carboplatin	4.2	0.005	8.0	ns	9	ns
Smit, 2009 [24]	II	240	Pemetrexed	2.8		7.6		4
Pectasides, 2005 [26]	II	130	Docetaxel + irinotecan	5.6	0.065	6.5	0.49	20	0.36
Pectasides, 2005 [26]	II	130	Docetaxel	4.8		6.4		14
Wachters, 2005 [27]	II	108	Docetaxel + irinotecan	15 weeks	0.42	27 weeks	0.69	10	NR
Wachters, 2005 [27]	II	108	Docetaxel	18 weeks		32 weeks		16
Georgoulias, 2005 [30]	II	147	Cisplatin + irinotecan	NR	NR	7.8	0.934	22.5	0.012
Georgoulias, 2005 [30]	II	147	Cisplatin			8.8		7

Data are presented as n, unless otherwise stated. PFS: progression-free survival; OS: overall survival; NR: not reported; ns: nonsignificant.